Radnor Capital Management LLC Has $530,000 Holdings in Solventum Co. (NYSE:SOLV)

Radnor Capital Management LLC lowered its position in Solventum Co. (NYSE:SOLVFree Report) by 21.1% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 8,024 shares of the company’s stock after selling 2,150 shares during the period. Radnor Capital Management LLC’s holdings in Solventum were worth $530,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of SOLV. Hollencrest Capital Management acquired a new position in shares of Solventum in the 2nd quarter valued at about $25,000. Modus Advisors LLC bought a new stake in Solventum in the fourth quarter worth approximately $25,000. Copeland Capital Management LLC bought a new position in shares of Solventum during the 3rd quarter worth approximately $26,000. Mather Group LLC. bought a new position in shares of Solventum during the 3rd quarter worth approximately $27,000. Finally, Twin Lakes Capital Management LLC acquired a new stake in shares of Solventum during the 2nd quarter worth approximately $29,000.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Stifel Nicolaus initiated coverage on shares of Solventum in a research note on Tuesday, October 8th. They set a “buy” rating and a $82.00 target price on the stock. Mizuho assumed coverage on shares of Solventum in a research report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price objective on the stock. Wolfe Research began coverage on Solventum in a research note on Thursday, September 26th. They issued a “peer perform” rating for the company. Morgan Stanley upped their price target on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Finally, Piper Sandler raised their price objective on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Solventum currently has a consensus rating of “Hold” and a consensus target price of $68.29.

Check Out Our Latest Analysis on Solventum

Solventum Trading Up 2.6 %

Shares of NYSE SOLV opened at $72.00 on Thursday. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The firm’s 50-day simple moving average is $69.18 and its 200 day simple moving average is $65.24. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $96.05.

About Solventum

(Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Featured Stories

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Co. (NYSE:SOLVFree Report).

Institutional Ownership by Quarter for Solventum (NYSE:SOLV)

Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.